CompletedPhase 1NCT01356485
Safety Study of MP4CO in Adult Sickle Cell Patients
Studying Hemoglobin C disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sangart
- Principal Investigator
- Tania Small, MDSangart, Inc.
- Intervention
- MP4CO(drug)
- Enrollment
- 32 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2012
Study locations (5)
- Hôpital Henri Mondor, Créteil, France
- Sickle Cell Unit, University of West Indies, Kingston, Jamaica
- Rafic Hariri University Hospital, Beirut, Lebanon
- Guy's Hospital, London, United Kingdom
- King's College London, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01356485 on ClinicalTrials.gov